Go to content
UR Home

Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor

URN to cite this document:
DOI to cite this document:
Kist, A. ; Ho, A. D. ; Räth, U. ; Wiedenmann, B. ; Bauer, A. ; Schlick, E. ; Kirchner, H. ; Männel, Daniela N.
Date of publication of this fulltext: 20 Jun 2011 06:14


Tumor necrosis factor (TNF), a protein predominantly produced by activated macrophages/monocytes, is presently available in recombinant, purified form for clinical trials. Intensive studies in many laboratories have shown that besides the tumorcytotoxic effects, TNF acts on a large array of different cells and has potent immunomodulatory activities. In a clinical phase I study, some immunologic ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons